Jonathan Henning, MD
Urology · Lincoln, NENPI 1518120823
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in NE, where the typical reported total is $2,774.
Across 148 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$337
- Caldera Medical, Inc$242
- Johnson & Johnson$230
- Astellas Pharma US Inc$211
- Dendreon Pharmaceuticals LLC$175
- Sumitomo Pharma America, Inc.$156
- plus $1K from 35 others
What the payments were for
- Food & beverage$2,807100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $337 |
| Caldera Medical, Inc | 1 | $242 |
| Johnson & Johnson | 15 | $230 |
| Astellas Pharma US Inc | 14 | $211 |
| Dendreon Pharmaceuticals LLC | 8 | $175 |
| Sumitomo Pharma America, Inc. | 7 | $156 |
| Pfizer | 10 | $141 |
| Myovant Sciences Inc. | 8 | $120 |
| Boston Scientific | 7 | $114 |
| EDAP Technomed Inc | 3 | $87 |
| Accord Healthcare, Inc. | 1 | $77 |
| Coloplast | 5 | $73 |
| Neotract Inc. | 1 | $65 |
| Stryker | 2 | $65 |
| Rochester Medical Corporation | 3 | $54 |
| Blue Earth Diagnostics | 3 | $53 |
| Alnylam Pharmaceuticals Inc. | 3 | $49 |
| Endo Pharmaceuticals Inc. | 3 | $43 |
| Merck | 3 | $41 |
| Novartis | 2 | $40 |
| Tolmar Pharmaceuticals, Inc. | 2 | $36 |
| Isoray, Inc | 1 | $36 |
| Davol Inc. | 1 | $34 |
| Tolmar, Inc. | 2 | $29 |
| KARL Storz Endoscopy-america | 2 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 2 | $28 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $22 |
| Civco Medical Instruments | 1 | $19 |
| Urogen Pharma, Inc. | 1 | $18 |
| Palette Life Sciences, Inc. | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| 180 Medical, Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Teleflex LLC | 1 | $15 |
| Endo USA, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $14 |
| Conmed Corporation | 1 | $14 |
| Laborie Medical Technologies Corp. | 1 | $12 |
| Medtronic | 1 | $11 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$242
How this compares
$2,807 in reported general payments places this provider in the 50th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 53 | $803,760 |
| ErleadaApalutamide | 11 | $153,530 |
| MyrbetriqMirabegron | 163 | $78,275 |
| OrgovyxRelugolix | 15 | $61,672 |
| GemtesaVibegron | 87 | $48,164 |
| Finasteride | 366 | $4,558 |
| Tamsulosin Hcl | 387 | $4,475 |
| Silodosin | 23 | $2,926 |
| Potassium Citrate ErPotassium Citrate | 36 | $2,009 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,862 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 20 | $1,800 |
| Solifenacin Succinate | 34 | $1,310 |
| Estradiol | 18 | $1,045 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 31 | $685 |
| Dutasteride | 23 | $486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $211 | $882,035216 claims |
| Johnson & JohnsonErleada | $230 | $153,53011 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $156 | $109,836102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 79 urology providers in Nebraska.
Other urology in Lincoln
- Antonio BeltranLincoln$51K
- Thomas BrushLincoln$15K
- Adam MuesLincoln$14K
- Lance WiebuschLincoln$13K
- David WiltfongLincoln$13K
- Logan McGuffeyLincoln$10K
- Aaron PomajzlLincoln$9K
- Tara KirkpatrickLincoln$8K
- Brandon HensleeLincoln$7K
- Andrew LepinskiLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.